Type 2 Diabetes Clinical Trial
— AR22Official title:
Effect of Moderate Alcohol Consumption on Cephalic Phase Reflex and Gene Expression of Adipose Tissue in Postmenopausal Women
Moderate alcohol consumption has consistently been associated with lowered risk of
developing type two diabetes mellitus compared to abstainers and heavy drinkers. However,
the underlying mechanism for the lower risk of type two diabetes is not clear.
Hypothesis: moderate alcohol consumption for four weeks changes gene expression pathways of
inflammatory status, insulin sensitivity and lipid and carbohydrate metabolism in adipose
tissue in both lean and obese postmenopausal women.
Hypothesis: Oral sensory stimulation by means of alcohol in the oral cavity will induce a
cephalic phase reflex as indicated by increased autonomic & endocrine responses in
postmenopausal women.
Status | Completed |
Enrollment | 24 |
Est. completion date | July 2008 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A to 65 Years |
Eligibility |
Inclusion Criteria: 1. Healthy as assessed by the health and lifestyle questionnaire (P8009 F02), physical examination and results of the pre-study laboratory tests 2. Caucasian postmenopausal females aged 65 years or younger at Day 01 of the study. 3. Body Mass Index (BMI) of 18 - 26 or 27 - 35 kg/m2. 4. Postmenopausal as assessed by self reported absence of menstrual periods for at least 12 months. 5. Alcohol consumption = 5 and = 22 standard units/week. 6. Normal Dutch eating habits as assessed by P8009 F02. 7. Voluntary participation. 8. Having given written informed consent. 9. Willing to comply with the study procedures, including refrain from drinking alcoholic drinks other then the wine provided by TNO during the entire study. 10. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years. 11. Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned. Exclusion Criteria: 1. Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study. 2. Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances. 3. Having a history of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disease and gastrointestinal disorders. 4. Use of medication that may affect the outcome of the study parameters. 5. Having a family history of alcoholism. 6. Smoking. 7. Not having appropriate veins for blood sampling/cannula insertion according to TNO. 8. Reported unexplained weight loss or gain in the month prior to the pre-study screening. 9. Reported slimming or medically prescribed diet. 10. Reported vegan, vegetarian or macrobiotic. 11. Recent blood donation (<1 month prior to the start of the study). 12. Not willing to give up blood donation during the study. 13. Personnel of TNO Quality of Life, their partner and their first and second degree relatives. 14. Not having a general practitioner. 15. Not willing to accept information transfer concerning participation in the study, or information regarding her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner. 16. Not willing your general practitioner to be notified upon participation in this study |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Netherlands | TNO Quality of Life | Zeist |
Lead Sponsor | Collaborator |
---|---|
TNO |
Netherlands,
Joosten MM, Balvers MG, Verhoeckx KC, Hendriks HF, Witkamp RF. Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab (Lond). 2010 J — View Citation
Joosten MM, de Graaf C, Rietman A, Witkamp RF, Hendriks HF. Short-term oral exposure to white wine transiently lowers serum free fatty acids. Appetite. 2010 Aug;55(1):124-9. doi: 10.1016/j.appet.2010.04.217. Epub 2010 May 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gene expression profiles in adipose tissue | after four weeks of intervention | No | |
Primary | Pancreatic Polypeptide (PP) | 0, 4, 8, 12, 16, 20 and 30 min after start of modified sham-feeding with either water, white wine or cake | No | |
Secondary | Cytokines excreted from PBMCs after in vitro stimulation with LPS | after four weeks of intervention | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |